SFMBT1

Across TCGA pan-cancer cohorts, SFMBT1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SFMBT1 data layer compared with 28 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher SFMBT1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SFMBT1 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

KIRC, BRCA, and LIHC are the cancer types where SFMBT1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.266	0.805	.017	12	view →
BRCA	DFS	Median	III,IV	0.141	0.796	<.001	6	view →
LIHC	OS	Median	All	0.173	0.688	.041	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
BLCA	DFS	Median	III,IV	1.000	0.271	.045	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SFMBT1–KIRC (OS)

Open the KIRC breakdown →